Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note published on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Aptose Biosciences Stock Performance

Aptose Biosciences stock opened at $0.36 on Wednesday. The firm has a market cap of $6.61 million, a price-to-earnings ratio of -0.12 and a beta of 1.26. Aptose Biosciences has a 1 year low of $0.33 and a 1 year high of $2.91. The firm’s 50 day moving average price is $0.38 and its two-hundred day moving average price is $0.64.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp boosted its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.